S&P 500
(0.06%) 5 251.58 points
Dow J
(0.02%) 39 769 points
Nasdaq
(-0.12%) 16 380 points
Oil
(1.95%) $82.94
Gas
(1.63%) $1.746
Gold
(1.25%) $2 240.40
Silver
(0.83%) $24.96
Platinum
(1.31%) $921.60
USD/EUR
(0.31%) $0.926
USD/NOK
(0.76%) $10.85
USD/GBP
(0.10%) $0.792
USD/RUB
(0.16%) $92.59

Realtime updates for Botanix Pharmaceuticals [BOT.AX]

Exchange: ASX Industry: Pharmaceuticals, Biotechnology & Life Sciences
Last Updated28 Mar 2024 @ 01:10

2.27% $ 0.225

Live Chart Being Loaded With Signals

Commentary (28 Mar 2024 @ 01:10):

Warning: Trying to access array offset on null in /home/getagraph/public_html/stock.php on line 302

Botanix Pharmaceuticals Limited engages in the research and development of dermatology and antimicrobial products in Australia. The company engages in development of novel treatments for common skin diseases and infections...

Stats
Today's Volume 9.85M
Average Volume 2.54M
Market Cap 354.41M
EPS $0 ( 2024-02-25 )
Last Dividend $95.85 ( 1996-10-03 )
Next Dividend $0 ( N/A )
P/E -22.50
ATR14 $0.00200 (0.89%)

Volume Correlation

Long: -0.07 (neutral)
Short: -0.59 (weak negative)
Signal:(46.785) Neutral

Botanix Pharmaceuticals Correlation

10 Most Positive Correlations
10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Botanix Pharmaceuticals Correlation - Currency/Commodity

The country flag -0.04
( neutral )
The country flag -0.55
( weak negative )
The country flag 0.00
( neutral )
The country flag 0.00
( neutral )
The country flag 0.00
( neutral )
The country flag -0.10
( neutral )

Botanix Pharmaceuticals Financials

Annual 2023
Revenue: $914 973
Gross Profit: $-3.05M (-332.90 %)
EPS: $-0.00790
Q2 2023
Revenue: $377 930
Gross Profit: $-3.02M (-800.40 %)
EPS: $-0.00380
Q4 2023
Revenue: $526 976
Gross Profit: $-2.19M (-414.79 %)
EPS: $-0.00350
Q3 2022
Revenue: $-142 531
Gross Profit: $-288 692 (202.55 %)
EPS: $-0.00180

Financial Reports:

No articles found.

Botanix Pharmaceuticals Dividends

(Q3/22) (Q4/22) (Q1/23) (Q2/23) (Q3/23) (Q4/23) (Q1/24) (Q2/24) (Q3/24) (Q4/24)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)

Botanix Pharmaceuticals Dividend Information - Ex Dividend Junior

Dividend Sustainability Score: 0 - low (50.00%) | Divividend Growth Potential Score: 0 - No dividend growth expected in the near future
Information
First Dividend $81.28 1994-02-18
Last Dividend $95.85 1996-10-03
Next Dividend $0 N/A
Payout Date 1996-10-25
Next Payout Date N/A
# dividends 6 --
Total Paid Out $510.23 --
Avg. Dividend % Per Year 0.00% --
Score 1.06 --
Div. Sustainability Score 0
Div.Growth Potential Score 0
Div. Directional Score 0 --
Next Divdend (Est)
(2024-04-29)
$0 Estimate 0.00 %
Dividend Stability
0.01 Very Bad
Dividend Score
1.06
Pay Frequency
Semi-Annually
Yearly Payout
Year Amount Yield

Warning: Undefined variable $stockPricesArray in /home/getagraph/public_html/stock.php on line 1111

Dividend Commentary

The company does not currently pay dividends. Given its current dividend status and a low Dividend Growth Potential Score (DGPS), there's minimal likelihood of dividends being initiated soon. Considering all factors, the near-term dividend outlook for the company remains unpromising.

Top 10 dividend Companies for ASX

Symbol Title Last dividend Frequency Years Dividend Yearly Dividend Score
WOR.AX Ex Dividend Knight 2023-08-29 Semi-Annually 0 0.00%
FEX.AX Ex Dividend Knight 2023-09-01 Annually 0 0.00%
PL8.AX Ex Dividend Knight 2023-09-14 Monthly 0 0.00%
ARG.AX Ex Dividend Knight 2023-08-25 Semi-Annually 0 0.00%
IAG.AX Ex Dividend Knight 2023-08-29 Semi-Annually 0 0.00%
RWC.AX Ex Dividend Knight 2023-09-07 Semi-Annually 0 0.00%
CBA.AX Ex Dividend Junior 2023-08-16 Semi-Annually 0 0.00%
LYL.AX Ex Dividend Knight 2023-09-21 Semi-Annually 0 0.00%
SXL.AX Ex Dividend Junior 2023-09-01 Annually 0 0.00%
CTE.AX Ex Dividend Knight 2023-09-07 Annually 0 0.00%

Dividend Sustainability Score (DSS)

RatioActual ValueWeightNormalized ValueScoreRange
netProfitMarginTTM-11.081.500-10.00-10.00[0 - 0.5]
returnOnAssetsTTM-0.2101.200-7.01-8.41[0 - 0.3]
returnOnEquityTTM-0.2931.500-4.37-6.56[0.1 - 1]
payoutRatioTTM0-1.00000[0 - 1]
currentRatioTTM9.500.80010.008.00[1 - 3]
quickRatioTTM8.090.80010.008.00[0.8 - 2.5]
cashRatioTTM7.991.50010.0010.00[0.2 - 2]
debtRatioTTM0-1.50000[0 - 0.6]
interestCoverageTTM-858.831.000-10.00-10.00[3 - 30]
operatingCashFlowPerShareTTM-0.007022.00-0.00234-0.00468[0 - 30]
freeCashFlowPerShareTTM-0.01862.00-0.00932-0.0186[0 - 20]
debtEquityRatioTTM0-1.50000[0 - 2.5]
grossProfitMarginTTM-5.761.000-10.00-10.00[0.2 - 0.8]
operatingProfitMarginTTM-11.101.000-10.00-10.00[0.1 - 0.6]
cashFlowToDebtRatioTTM01.000-1.111-1.111[0.2 - 2]
assetTurnoverTTM0.01900.800-3.21-2.57[0.5 - 2]
Total Score-3.67

Dividend Growth Score (DGS)

RatioActual ValueWeightNormalized ValueScoreRange
peRatioTTM-33.011.000-3.440[1 - 100]
returnOnEquityTTM-0.2932.50-2.81-6.56[0.1 - 1.5]
freeCashFlowPerShareTTM-0.01862.00-0.00621-0.0186[0 - 30]
dividendYielPercentageTTM01.50000[0 - 0.4]
operatingCashFlowPerShareTTM-0.007022.00-0.00234-0.00468[0 - 30]
payoutRatioTTM01.50000[0 - 1]
pegRatioTTM0.1111.500-2.590[0.5 - 2]
operatingCashFlowSalesRatioTTM-11.171.000-10.000[0.1 - 0.5]
Total Score-2.44

Botanix Pharmaceuticals

Botanix Pharmaceuticals Limited engages in the research and development of dermatology and antimicrobial products in Australia. The company engages in development of novel treatments for common skin diseases and infections. Its product pipeline includes Sofpironium Bromide, a drug in development for the treatment of primary axillary hyperhidrosis that has completed Phase 3 clinical programs; BTX 1503, a transdermal gel formulation for the treatment of serious acne in adults and teenagers that has completed Phase II clinical trials; BTX 1801, which has completed Phase IIb clinical trials for the treatment of staphylococcus aureus and methicillin resistant staphylococcus aureus; BTX 1702 that is in Phase IIb clinical trials for the treatment of papulopustular rosacea; and BTX 1204A for the treatment of atopic dermatitis. The company was incorporated in 1984 and is based in Leederville, Australia.

About Live Signals

The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.

The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators